Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 30 systematic review(s)/meta-analysis(es). ^[1-30]
• Psoriatic Arthritis (PA): Golimumab demonstrated very low certainty of evidence in achieving Psoriatic Arthritis Response Criteria (PsARC) at 6 months, showing less effectiveness compared to Etanercept, Infliximab, and Certolizumab Pegol. It was not among the top treatments for achieving American College of Rheumatology (ACR) 50 at 6 months, as Secukinumab, Infliximab, and Adalimumab were more effective.
• Fatigue in Rheumatic and Musculoskeletal Diseases (I-RMDs): In rheumatoid arthritis, Golimumab significantly reduced fatigue at 24 weeks compared to placebo (mean difference (MD)=-5.27, p<0.001).
• Ankylosing Spondylitis (AS): Golimumab led to significant improvements in Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), total back pain, Jenkins Sleep Evaluation Questionnaire (JSEQ), SF-36 Physical Component Summary (PCS), and SF-36 Mental Component Summary (MCS) scores relative to placebo. The 100 mg dose showed greater efficacy than the 50 mg dose but was associated with a higher incidence of serious adverse events.
• Juvenile Idiopathic Arthritis-associated Uveitis (JIA-U): Golimumab achieved a 65% (95% confidence interval (CI) 42-86%) rate of intraocular inflammation control, higher than Infliximab but lower than Adalimumab.
• Etanercept and Golimumab were associated with a lower risk of serious infection compared to other tumor necrosis factor (TNF) inhibitors, with Golimumab specifically noted to have fewer safety concerns relative to Certolizumab Pegol and Infliximab, which had higher risks of serious infections.
• For Psoriatic Arthritis, Golimumab, along with Secukinumab and Adalimumab, exhibited very low certainty of evidence for safety, with no significant differences observed in the risk of serious adverse events between Golimumab and placebo.
• In long-term follow-ups and observational studies, Golimumab demonstrated a stable safety profile comparable to other biologics, showing no increase in adverse events with dose escalation in conditions like Ulcerative Colitis and Crohn's Disease.
• There is no population types or subgroups information available in the reviewed studies.